drugset / Trial / NCT00381095

A Study To Evaluate Pregabalin In The Treatment Of Moderate To Severe Chronic Bone Pain Related To Metastatic Cancer

NCT00381095

Phase 4 Terminated 152 enrolled Viatris Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to assess the analgesic efficacy of flexibly-dosed pregabalin in the adjunctive treatment of subjects with cancer-induced bone pain.

Timeline

Start
2006-12
Primary completion
2010-10
Completion
2010-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Pregabalin Small molecule 100 mg
Subject Pregabalin Small molecule 150 mg
Subject Pregabalin Small molecule 300 mg
Subject Pregabalin Small molecule 600 mg